Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 catch-up vaccination study of a 21-valent pneumococcal conjugate vaccine in healthy children and adolescents
2024-512271-13-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal conjugate vaccine and Prevnar 20 in pneumococcal disease (2 arms), sponsored by Sanofi. Primary endpoints: Immediate adverse events, Solicited reactogenicity and 6 more. Planned start Mar 2025; status: authorised.
02
Drugs
pneumococcal conjugate vaccinePrevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2024-512271-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512271-13-00.